The patent grant is a modest positive but does not alter the high-risk clinical-stage profile. Monitor for an IND filing and initiation of clinical trials, which represent the next major catalyst. The $22M market cap leaves limited room for adverse financing news.
Price Chart
Executive Summary
NewcelX announced a Brazilian patent grant for its lead T1D cell therapy candidate NCEL-101, extending manufacturing-process IP protection until November 2036. This follows a recent successful FDA Type B Pre-IND meeting, adding a minor positive catalyst for a pre-revenue clinical-stage company with a $22M market cap.
Key Facts
- Brazilian Patent and Trademark Office issued Patent No. BR 112018010946-0 covering NCEL-101 cell selection and enrichment technology.
- Patent protects manufacturing process of NCEL-101 until November 2036.
- Brazil has approximately 500,000 people living with T1D, with prevalence growing at 4.4% annually.
- NewcelX recently completed a successful FDA Type B Pre-IND meeting for NCEL-101 in combination with tegoprubart.
- NCEL-101 preclinical data: ~60% beta cells co-express insulin and NKX6.1, 99.98% endocrine lineage, >96% non-proliferative cells.
Financial Impact
No immediate financial impact; strengthens IP portfolio for future licensing/partnering in a large T1D market (Brazil).
Risk Factors
- Going concern risk flagged in forward-looking statements.
- Clinical-stage with no approved products or revenue; dependent on future financing and trial success.
- Brazil patent alone does not guarantee commercial success; regulatory and competitive risks remain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-078173 |
| Document: ea0297934-6k_newcelx.htm | 0001213900-26-078173 |
| Document: 0001213900-26-078173-index-headers.html | 0001213900-26-078173 |
| Document: 0001213900-26-078173-index.html | 0001213900-26-078173 |
| Document: 0001213900-26-078173.txt | 0001213900-26-078173 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | EFFECT | $2.86 $3.08 | ▼ −7.52% | ▼ −8.19% | $2.64 (+7.69%) |
Sep 18, 2026 5w ago | 6-K | $2.97 $2.92 | ▲ +1.68% | ▲ +0.66% | $2.64 (+11.11%) |
Aug 27, 2026 8w ago | EFFECT | $3.42 $3.35 | ▲ +2.05% | ▲ +1.28% | $2.64 (+22.81%) |
Jul 31, 2026 12w ago | 6-K | $3.49 $3.31 | ▼ −5.16% | ▼ −8.67% | $2.64 (−24.36%) |
Jul 15, 2026 14w ago | 6-K | $3.93 $3.65 | ▼ −7.12% | ▼ −6.14% | $2.64 (−32.82%) |
Jul 8, 2026 15w ago | 6-K | $4.23 $3.98 | ▼ −5.91% | ▼ −6.77% | $2.64 (−37.59%) |
Jul 1, 2026 16w ago | 6-K | $3.85 $4.01 | ▲ +4.16% | ▲ +3.89% | $2.64 (−31.43%) |
Jun 30, 2026 16w ago | 6-K | $3.85 $4.01 | ▲ +4.16% | ▲ +3.89% | $2.64 (−31.43%) |
Jun 18, 2026 18w ago | EFFECT | $3.31 $3.55 | ▼ −7.25% | ▼ −8.92% | $2.64 (+20.24%) |
Jun 5, 2026 20w ago | 6-K | $3.24 $3.20 | ▼ −1.23% | ▼ −3.35% | $2.64 (−18.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers